AZN:LON
AstraZeneca PLC (US)
GBXÂ 11,870.00
arrow_downward
-1.35%(-162.00) 1D
Oct 2, 4:36:52 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
GBXÂ 11,800.00
High
GBXÂ 12,094.00
Low
GBXÂ 11,790.00
Mkt. cap
245.07B
Avg. vol.
2.84M
Volume
1.62M
Dividend
2.01%
Quarterly dividend
GBXÂ 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
23.42
52-wk high
GBXÂ 15,732.00
52-wk low
GBXÂ 9,892.00
EPS
GBXÂ 5.07
Shares outstanding
1.55B
No. of employees
96K
Open
GBXÂ 11,800.00
High
GBXÂ 12,094.00
Low
GBXÂ 11,790.00
Mkt. cap
245.07B
Avg. vol.
2.84M
Volume
1.62M
Dividend
2.01%
Quarterly dividend
GBXÂ 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
23.42
52-wk high
GBXÂ 15,732.00
52-wk low
GBXÂ 9,892.00
EPS
GBXÂ 5.07
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
AD HOC NEWS
·
5 minutes ago
AstraZeneca agrees to invest in Summit as AstraZeneca stock costs EUR 139.63
GuruFocus
·
16 hours ago
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Ph
The Business Journals
·
18 hours ago
Innovation roundup: Carnegie Mellon in Miami, AstraZeneca's $2B investment
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com